These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
326 related articles for article (PubMed ID: 17168449)
1. [Advances in the treatment of metastatic colorectal cancer with bevacizumab]. Longo F; Mansueto G Tumori; 2006; 92(5):suppl 1-12. PubMed ID: 17168449 [No Abstract] [Full Text] [Related]
3. Pathologic complete response to neoadjuvant FOLFOX in combination with bevacizumab in unresectable metastatic colorectal carcinoma. Duffy A; Shia J; Huitzil-Melendez FD; Fong Y; O'Reilly EM Clin Colorectal Cancer; 2008 Mar; 7(2):140-3. PubMed ID: 18501074 [TBL] [Abstract][Full Text] [Related]
4. Current role of bevacizumab in colorectal cancer. Saltz L Clin Adv Hematol Oncol; 2009 Jun; 7(6):375-6. PubMed ID: 19606071 [No Abstract] [Full Text] [Related]
5. The treatment of colorectal carcinoma: standard chemotherapy and beyond. Eng C; Abbruzzese JL Clin Adv Hematol Oncol; 2004 Sep; 2(9):592-8. PubMed ID: 16163242 [TBL] [Abstract][Full Text] [Related]
6. Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer. Hurwitz H; Kabbinavar F Oncology; 2005; 69 Suppl 3():17-24. PubMed ID: 16301832 [TBL] [Abstract][Full Text] [Related]
7. The use cetuximab after oxaliplatin-based chemotherapy in a patient with metastatic colorectal cancer. Malik Z; Eng C Clin Adv Hematol Oncol; 2007 Jan; 5(1 Suppl 1):4-7. PubMed ID: 17491584 [No Abstract] [Full Text] [Related]
8. [Bevacizumab in the treatment of colorectal carcinoma: news from ASCO 2008]. Mansueto G; Longo F Tumori; 2008; 94(4):suppl 1-14. PubMed ID: 18822711 [No Abstract] [Full Text] [Related]
9. Bevacizumab in the treatment of colorectal cancer. Marshall JL Clin Adv Hematol Oncol; 2007 Jan; 5(1 Suppl 1):8-9. PubMed ID: 17491585 [No Abstract] [Full Text] [Related]
10. Dual biologic therapy in the first-line mCRC setting: implications of the CAIRO2 study. Chu E Clin Colorectal Cancer; 2008 Jul; 7(4):226. PubMed ID: 18650190 [No Abstract] [Full Text] [Related]
11. Highlights from the 42nd Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA, June 2006. Clin Colorectal Cancer; 2006 Jul; 6(2):109-13. PubMed ID: 16945165 [No Abstract] [Full Text] [Related]
12. Short time infusion of bevacizumab in combination with 5FU-based chemotherapy as first-line therapy in a non-selective patient group with metastatic colorectal cancer. Dohn LH; Jensen BV; Larsen FO Acta Oncol; 2010 Apr; 49(3):395-6. PubMed ID: 20001495 [No Abstract] [Full Text] [Related]
13. EGFR antibodies in colorectal cancer: where do they belong? Grothey A J Clin Oncol; 2010 Nov; 28(31):4668-70. PubMed ID: 20921457 [No Abstract] [Full Text] [Related]
14. Bevacizumab plus irinotecan-based regimens in the treatment of metastatic colorectal cancer. Heinemann V; Hoff PM Oncology; 2010; 79(1-2):118-28. PubMed ID: 21088438 [TBL] [Abstract][Full Text] [Related]
15. [Transition of chemotherapy for metastatic colorectal cancer and recent advances]. Muro K Nihon Rinsho; 2010 Jun; 68(6):1143-9. PubMed ID: 20535969 [TBL] [Abstract][Full Text] [Related]
17. Metastatic colorectal cancer: is there one standard approach? Saltz LB Oncology (Williston Park); 2005 Aug; 19(9):1147-54; discussion 1154, 1157-8, 1160. PubMed ID: 16255132 [TBL] [Abstract][Full Text] [Related]
18. FOLFOXIRI and bevacizumab in metastatic colorectal cancer. Rahman A Lancet Oncol; 2014 Dec; 15(13):e590. PubMed ID: 25499288 [No Abstract] [Full Text] [Related]
19. [Progress of chemotherapy in colorectal cancer]. Komatsu Y Gan To Kagaku Ryoho; 2007 Nov; 34(11):1771-6. PubMed ID: 18064761 [No Abstract] [Full Text] [Related]
20. [The development of the first line treatment of metastatic colorectal cancer (mCRC)]. Landherr L; Nagykálnai T Magy Onkol; 2009 Sep; 53(3):237-46. PubMed ID: 19793687 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]